AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元核心哮喘疗法已进入III期临床

智通财经网02-05

智通财经APP获悉，专注于哮喘治疗的AI生物科技公司Generate Biomedicines(GENB.US)周三向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多1亿美元。该公司利用AI药物发现平台开发重症哮喘疗法，其核心候选药物已进入关键性III期临床试验阶段。Generate Biomedicines宣称，其AI驱动的Generate平台是一个紧密整合的“设计-构建-测试-学习...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2609321873?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2026-02-05 14:52","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2609321873","market":"hk","top_or_hot":-1,"title":"AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，专注于哮喘治疗的AI生物科技公司Generate  Biomedicines(GENB.US)周三向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多1亿美元。该公司利用AI药物发现平台开发重症哮喘疗法，其核心候选药物已进入关键性III期临床试验阶段。Generate  Biomedicines宣称，其AI驱动的Generate平台是一个紧密整合的“设计-构建-测试-学习...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401992.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-05 14:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1401992.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，专注于哮喘治疗的AI生物科技公司Generate  Biomedicines(GENB.US)周三向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多1亿美元。该公司利用AI药物发现平台开发重症哮喘疗法，其核心候选药物已进入关键性III期临床试验阶段。Generate  Biomedicines宣称，其AI驱动的Generate平台是一个紧密整合的“设计-构建-测试-学习...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401992.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1401992.html","article_id":"2609321873","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609321873","pubTimestamp":1770274343,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"专注于哮喘治疗的AI生物科技公司Generate Biomedicines(GENB.US)周三向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多1亿美元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159837":"生物科技","III":"信息服务","LABU":"三倍做多标普生物-Direxion","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4134":"信息科技咨询与其它服务"},"translate_title":"AI biotechnology company Generate (GENB.US) plans to raise US $100 million in an IPO in the United States. Core asthma therapy has entered phase III clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159837":1.5,"LABU":1.5,"III":1.5},"content_text":"智通财经APP获悉，专注于哮喘治疗的AI生物科技公司Generate  Biomedicines(GENB.US)周三向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多1亿美元。该公司利用AI药物发现平台开发重症哮喘疗法，其核心候选药物已进入关键性III期临床试验阶段。Generate  Biomedicines宣称，其AI驱动的Generate平台是一个紧密整合的“设计-构建-测试-学习”闭环系统，旨在生成具有治疗相关性的专有数据及差异化分子解决方案。公司表示，其技术潜力已通过三款计算设计的蛋白质成功进入人体临床试验得到验证，其中进展最快的GB-0895是一款研究性长效抗胸腺基质淋巴细胞生成素单克隆抗体，目前正在为重症哮喘开展关键性III期临床试验的患者招募工作。这家总部位于马萨诸塞州萨默维尔的公司成立于2018年，计划在纳斯达克上市，股票代码暂定为“GENB”。该公司曾于2025年12月23日秘密提交上市申请。本次发行由高盛、摩根士丹利、Piper  Sandler、古根海姆证券和康托菲茨杰拉德联合担任簿记管理人。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609321873","isCrawlerRequest":true}

AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床

精彩评论

AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元核心哮喘疗法已进入III期临床